Multiple tumor-associated antigens from DIPG tumor cells (DIPG TAAs)

Multiple tumor-associated antigens (TAAs) from Diffuse Intrinsic Pontine Glioma (DIPG) tumor cells represent a diverse set of molecular targets used in the development of immunotherapies for this lethal pediatric brainstem cancer. These antigens include the pathognomonic H3 K27M mutant histone, which drives oncogenesis through global epigenetic remodeling, and various surface-expressed molecules such as the disialoganglioside GD2, the immune checkpoint protein B7-H3 (CD276), IL-13Rα2, and EphA2 (Vitanza et al., 2019, PubMed). Because DIPG is characterized by significant inter- and intra-tumoral heterogeneity, targeting a single antigen often leads to immune escape and disease recurrence. Consequently, researchers are developing multi-antigen targeting strategies, including polyvalent peptide vaccines and multi-specific chimeric antigen receptor (CAR) T-cell therapies, to improve therapeutic efficacy and durability (Mount et al., 2018, Nature Medicine). These targets are essential for overcoming the immunosuppressive microenvironment of the central nervous system and providing a precision medicine approach to a disease that currently lacks effective conventional treatments. Clinical trials are currently evaluating the safety and efficacy of these multi-antigen approaches, with a focus on managing unique challenges such as tumor inflammation-associated neurotoxicity in the critical structures of the brainstem (Majzner et al., 2017, Clinical Cancer Research).

Other names

DIPG-associated antigensDiffuse Intrinsic Pontine Glioma antigensDIPG TAAsDiffuse midline glioma antigens

Induction of targeted immune-mediated destruction of tumor cells through T-cell activation or antibody-dependent mechanisms against specific DIPG-associated molecular markers.